Item 5.07. Submission of Matters to a Vote of Security Holders.
OnJune 2, 2021 ,ANI Pharmaceuticals, Inc. (the "Company") held its 2021 annual meeting of stockholders (the "Annual Meeting"). The following sets forth the matters that were voted upon by the Company's stockholders at the Annual Meeting and the voting results for such matters. These matters are described in more detail in the Company's definitive proxy statement on Schedule 14A filed with theSecurities and Exchange Commission onApril 29, 2021 (the "Proxy Statement").
1. The Company's stockholders voted to elect the following directors, each to
serve until his or her successor has been duly elected and qualified or until
his or her earlier resignation or removal. The final voting results are as follows: Nominee For Against Abstentions Broker Non-Votes 1. Robert E. Brown, Jr. 9,466,522 325,176
3,376 797,905 2. Thomas Haughey 9,534,467 257,199 3,408 797,905 3. Nikhil Lalwani 9,655,278 136,331 3,465 797,905
4. David B. Nash, M.D., M.B.A. 9,409,937 381,762
3,375 797,905 5. Antonia R. Pera 9,656,007 135,634 3,433 797,905 6. Jeanne A. Thoma 9,652,137 139,542 3,395 797,905 7. Patrick D. Walsh 9,392,837 398,827 3,410 797,905
2. The Company's stockholders approved, on a non-binding advisory basis, the
compensation of the Company's named executive officers, as described in the
Proxy Statement. The final voting results are as follows:
For Against Abstentions Broker Non-Votes 9,417,485 328,111 49,478 797,905
3. The Company's stockholders ratified the appointment of
Company's independent registered public accounting firm for the year ending
December 31, 2021 . The final voting results are as follows: For Against Abstentions Broker Non-Votes 10,546,523 42,147 4,309 --
4. The Company's stockholders approved in connection with the Company's pending
acquisition of
(a) 2,466,667 shares of common stock to certain members of Novitium and
(b) 25,000 shares of Series A Convertible Preferred Stock to Ampersand 2020
Limited Partnership. The final voting results are as follows: For Against Abstentions Broker Non-Votes 9,727,248 57,285 10,541 797,905
Item 7.01. Regulation FD Disclosure.
OnJune 4, 2021 , the Company posted an investor presentation to the Investor Relations section of its website at www.anipharmaceuticals.com in connection with a presentation by its executives at an investor conference. A copy of the investor presentation is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, are furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit Description 99.1 Investor Presentation -June 2021 . 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
© Edgar Online, source